Monte Rosa Therapeutics, (id:8159 GLUE)
8.49 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 3:53:08 PM)
Exchange closed, opens in 17 hours 36 minutes
About Monte Rosa Therapeutics,
Market Capitalization 521.60M
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
| Headquarters (address) |
321 Harrison Avenue Boston 02118 MA United States |
| Phone | 617 949 2643 |
| Website | https://www.monterosatx.com |
| Employees | 133 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | GLUE |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 2.91 - 12.40 |
| Market Capitalization | 521.60M |
| P/E trailing | -3.23 |
| P/E forward | -5.66 |
| Price/Sale | 34.83 |
| Price/Book | 2.54 |
| Beta | 1.30 |
| EPS | -1.78 |
| EPS United States (ID:6, base:3402) | 24.22 |